Thank you , very interesting...

" Interim results from dose-escalation phase 1 trial show partial responses in 10 patients .
On the safety front , however , there were serious and life-threatening treatment -related adverse evens "

So patients need to chose , die from cancer , or possibly from side effects of medicine .. those are common choices for cancer patients until now , possibly , I mean , things maybe changing.......

Go Leronlimab...



All , IMO as always..